SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
SciSparc would be entitled to receive consideration valued at $3 million in Polyrizon securities, as well as potential milestone fees...
Autism
PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection
Company provides update on regulatory progress towards US NDA submission TARRYTOWN, NY / ACCESSWIRE / August 27, 2024 / PaxMedica,...
Key Highlights of Lighthouse Fusion
Multidisciplinary Clinical Expertise Therapy Room Therapy Room at Lighthouse Autism Center Speech Therapy Speech Therapy session at Lighthouse Autism Center...
Free Online Support & Resources for Individuals with Siblings on the Autism Spectrum
JUPITER, Fla., Aug. 22, 2024 /PRNewswire/ -- Having a sibling with autism spectrum disorder (ASD) can at times leave an...
RethinkBH Debuts Enhanced Analytics to Optimize ABA Clinical Programming and Practice Management
New dashboards surface insights on service pacing, authorization utilization, total trials and more to improve operational efficiency, decision making and...
Lighthouse Autism Center Partners with Local Government Officials to Highlight Autism Services and Community Impact
Mayor Oler of Richmond, Indiana Visits Lighthouse Autism Center in Richmond, Indiana Therapy Room Therapy Room at Lighthouse Autism Center...
Dr. Greg Hanley Joins Action Behavior Centers
Executive Director of Compassionate Care AUSTIN, TX / ACCESSWIRE / August 12, 2024 / Action Behavior Centers is thrilled to...
Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance
CAPLYTA Q2 2024 net product sales were $161.3 million, compared to $110.1 million for the same period in 2023, representing a...
SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug
SciSparc has been collaborating with Clearmind Medicine to create effective treatments for obesity and metabolic syndrome by combining SciSparc’s Palmitoylethanolamide...
Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program...
AbleNet, Inc. Can Now Serve and Support California Medi-Cal Clients with the QuickTalker Freestyle Speech Device
California is dedicated to supporting their state Medicaid recipients with the best possible healthcare professionals and AbleNet has been added...
Healthcare IT Market size is set to grow by USD 199.8 billion from 2024-2028, Increasing focus on improving quality of services and efficiency to boost the market growth, Technavio
NEW YORK, July 30, 2024 /PRNewswire/ -- The global healthcare IT market size is estimated to grow by USD 199.8...
Yamo Pharmaceuticals Announces Positive Topline Results from Phase 2 Study of L1-79 for the Treatment of the Core Symptoms of Autism
Data shows L1-79 offers a statistically significant improvement compared to placebo in socialization, as well as the investigator- and parent-rated...
Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference
ANAVEX®2-73 corrects directly to humans’ translatable EEG biomarkers in a model of Fragile X Syndrome (FXS) Therapeutic potential to address...
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
Presentations will include an encore of the positive interim Phase 1/2 results presented in April at the 76th Annual American...
Beyond Air® to Report First Fiscal Quarter 2025 Financial Results on August 6
GARDEN CITY, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a...
Spinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 in Fragile X Syndrome
U.S. FDA has granted Orphan Drug Designation to SPG601 for the Treatment of Fragile X Syndrome SPG601 is a novel...
North Shore Pediatric Therapy Expands Locations & Offers Rapid Early Autism Testing Amidst National Waitlists
Autism testing for kids 4 and under in Arlington Heights, Deerfield, and Naperville fills a much-needed gap for local families.CHICAGO,...
Urban Community Healthcare Center Launches New Program to Address Racial/Economic Disparities in Pediatric Developmental Screenings
Dr. Michael Oanea Hired to Pediatric Team at Whittier Street Health, Roxbury, MABOSTON, MA / ACCESSWIRE / July 18, 2024...
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
SciSparc will receive additional payments and execution fees if certain milestones are met TEL AVIV, Israel, July 17, 2024 (GLOBE...